A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 25 (7) , 497-510
- https://doi.org/10.2165/00002018-200225070-00004
Abstract
Chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide. Until recently, interferon (IFN)-α was the only approved drug for the treatment of chronic HBV infection....Keywords
This publication has 62 references indexed in Scilit:
- Is Lamivudine Effective on Precore/Core Promoter Mutants of Hepatitis B Virus?Hepatology, 2000
- Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis BThe Journal of Infectious Diseases, 2000
- Selection of Multiresistant Hepatitis B Virus during Sequential Nucleoside‐Analogue TherapyThe Journal of Infectious Diseases, 2000
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatmentHepatology, 1999
- Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.Journal of Clinical Investigation, 1998
- Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in FranceJournal of Hepatology, 1994
- Chronic type B hepatitis and the “healthy” Hbsag carrier stateHepatology, 1987